Vir Biotechnology Inc (VIR) Stock Price, Quote & News

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 906 4324

Website: www.vir.bio

Address:

1800 Owens Street, Suite 900, San Francisco, United States

Tacto Aug. 20 at 9:08 AM

$VIR What's with the $4.09 transaction? Did the goons vanish the bid, or how in the hell does that come about?

0 · Reply

Pharm_Hand Aug. 14 at 4:58 PM

$VIR Who told me again that selling at $12.60 in January was stupid?

1 · Reply

Mhand Aug. 12 at 1:11 PM

$VIR It may get ugly today. A million shares have been gobbled up by the sorts this morning. We'll probably see 2 million or more shares for volume today.

1 · Reply

Abovezero0000 Aug. 11 at 7:05 PM

$VIR Mary ann was nicknamed ”The Dealmaker” in her previous role at Bayer AG. Since they’re so confident in their hepatitis D program that they’re willing to ride the company’s cash/stock price to zero just in time for the data release, why is it so hard for you and your team to go out and make a deal? We have seen only one deal/partnership made (Sanofi) under Mary Ann’s leadership as CEO and that was to cover up the hepatits B failure. She comes from a position in her previous role where she “spearheaded the company’s external innovation, resulting in more than 50 new alliances and company acquisitions”. We have seen practically no attempts from this leadership team to grow the company’s external innovation but rather soley focus on the internal, which is directly why their was a massive sell off after their quarterly earnings call. Investors are tired of hearing the same crap on the quarterly calls, either go out there and find new partnerships ASAP for the company or seek a buyout.

2 · Reply

Mhand Aug. 11 at 5:22 PM

$VIR Brutal. Heading to 3's.

0 · Reply

Dunnieboy1 Aug. 11 at 4:22 PM

$VIR another all time low $4.21, wonderful

1 · Reply

Abovezero0000 Aug. 8 at 6:09 PM

$VIR Current Market Cap= $590M Pipeline is easily worth $1B at minimum + the $892M in cash/cash equivalents. This could easily get bought out for $2B-$3B range, if big biotech was smart they would be throwing $VIR some offers right now.

1 · Reply

Electhim Aug. 8 at 3:48 PM

$VIR never thought in a million years this stock would go this low. Still some good pipeline left and plenty of cash.

1 · Reply

Dunnieboy1 Aug. 7 at 11:08 PM

$VIR n a report released today, Sean McCutcheon from Raymond James reiterated a Buy rating on Vir Biotechnology, with a price target of $12.00. The company’s shares opened today at $4.82.

1 · Reply

PiazzaDelivers Aug. 7 at 9:14 PM

$VIR enough cash til mid 27 so basically 2 years. Big pops coming on trials.

0 · Reply

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 18 days ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 8:05 AM EDT - 18 days ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 24 days ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 24, 2025, 8:05 AM EDT - 4 weeks ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 23, 2025, 12:10 PM EDT - 4 weeks ago

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 22, 2025, 4:05 PM EDT - 4 weeks ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:00 AM EDT - 2 months ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

May 28, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 20, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 12, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 9, 2025, 6:00 AM EDT - 3 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025, 3:37 PM EDT - 3 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 7, 2025, 11:21 PM EDT - 3 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 24, 2025, 9:30 AM EDT - 4 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Mar 21, 2025, 7:10 AM EDT - 5 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 13, 2025, 8:05 AM EDT - 5 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Feb 26, 2025, 11:22 PM EST - 6 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 13, 2025, 6:10 PM EST - 7 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 10, 2025, 2:32 PM EST - 8 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 9, 2025, 9:00 AM EST - 8 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 8, 2025, 12:28 PM EST - 8 months ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 7:45 AM EST - 8 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 8 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 12:57 PM EST - 9 months ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 12, 2024, 4:05 PM EST - 9 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Nov 26, 2024, 9:30 AM EST - 9 months ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 9 months ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 9:15 PM EST - 9 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 4:05 PM EST - 9 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 15, 2024, 11:00 AM EST - 10 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 5, 2024, 11:29 AM EST - 10 months ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Oct 31, 2024, 11:12 PM EDT - 10 months ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 10 months ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 17, 2024, 4:30 PM EDT - 11 months ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 15, 2024, 8:16 AM EDT - 11 months ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 3, 2024, 4:00 PM EDT - 11 months ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 10, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Aug 22, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 1, 2024, 10:10 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:02 PM EDT - 1 year ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 17, 2024, 4:47 PM EDT - 1 year ago

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Tacto Aug. 20 at 9:08 AM

$VIR What's with the $4.09 transaction? Did the goons vanish the bid, or how in the hell does that come about?

0 · Reply

Pharm_Hand Aug. 14 at 4:58 PM

$VIR Who told me again that selling at $12.60 in January was stupid?

1 · Reply

Mhand Aug. 12 at 1:11 PM

$VIR It may get ugly today. A million shares have been gobbled up by the sorts this morning. We'll probably see 2 million or more shares for volume today.

1 · Reply

Abovezero0000 Aug. 11 at 7:05 PM

2 · Reply

Mhand Aug. 11 at 5:22 PM

$VIR Brutal. Heading to 3's.

0 · Reply

Dunnieboy1 Aug. 11 at 4:22 PM

$VIR another all time low $4.21, wonderful

1 · Reply

Abovezero0000 Aug. 8 at 6:09 PM

1 · Reply

Electhim Aug. 8 at 3:48 PM

$VIR never thought in a million years this stock would go this low. Still some good pipeline left and plenty of cash.

1 · Reply

Dunnieboy1 Aug. 7 at 11:08 PM

$VIR n a report released today, Sean McCutcheon from Raymond James reiterated a Buy rating on Vir Biotechnology, with a price target of $12.00. The company’s shares opened today at $4.82.

1 · Reply

PiazzaDelivers Aug. 7 at 9:14 PM

$VIR enough cash til mid 27 so basically 2 years. Big pops coming on trials.

0 · Reply

sunny84 Aug. 7 at 7:55 PM

$VIR brutal drop !

0 · Reply

wintogether Aug. 7 at 7:38 PM

$VIR the cash is dwindling fast given the start of these trials and licensor milestones being hit. Hence the punishment from the market. Unless the results are good, the market prices this for BK soon. That's how risk-adverse the market currently is toward biotech companies.

1 · Reply

Dunnieboy1 Aug. 7 at 6:27 PM

$VIR all time low $4.27

0 · Reply

Dunnieboy1 Aug. 7 at 5:00 PM

$VIR i’ll better we either rally into the close or tomorrow, at least a 10% bounce from this point.

0 · Reply

Doom_Gloom_AR Aug. 7 at 2:58 PM

$VIR why the drop i have no position, but this is a very promising company. TCE is going to be big. Been waiting on better values and more data.

2 · Reply

scott52 Aug. 7 at 2:41 PM

$VIR I mean, honestly, what's the point of doing nine figure clinical trials if there's no money to be made selling drugs or treatments? Trump doesn't understand anything. He's just a populist and a bully. He's destroying this sector of the economy. And my portfolio along with it.

1 · Reply

deezstocks3 Aug. 7 at 2:35 PM

$VIR scooping more here. 😬

0 · Reply

Dunnieboy1 Aug. 7 at 1:28 PM

$VIR Barclays analyst Gena Wang maintained a Buy rating on Vir Biotechnology today and set a price target of $31.00. The company’s shares closed yesterday at $5.08

4 · Reply

Mjcwo Aug. 6 at 5:19 PM

$INMB chatter heating up on Reddit &amp; WSB — short squeeze fuel incoming. Shorts still hanging on, but one well-timed PR during earnings tomorrow could ignite fireworks. Don’t sleep on this sleeper. $XBI $MRNA $BMRN $VIR #biotech #shortsqueeze 🔥🔥

2 · Reply

Dunnieboy1 Aug. 5 at 8:42 PM

$VIR SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025.

0 · Reply

Estimize Aug. 4 at 12:03 PM

Wall St is expecting -0.72 EPS for $VIR Q3 [Reporting 10/30 AMC] http://www.estimize.com/intro/vir?chart=historical&metric_name=eps&utm_con

0 · Reply

VIR_Tical1 Jul. 31 at 1:50 PM

$VIR * First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite bulevirtide treatment * ECLIPSE 2 is a pivotal trial designed to support global marketing applications, including in the U.S. and Europe

0 · Reply

Market Cap	636.24M
Revenue (ttm)	74.21M
Net Income (ttm)	-521.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-703.36%
Debt to Equity Ratio	0.00

Volume	1,186,900
Avg Vol	1,122,418
Day's Range	N/A - N/A
Shares Out	138.92M
Stochastic %K	80%
Beta	1.18
Analysts	Strong Sell
Price Target	$17.62